Transarterial Embolization for Soft Tissue Sarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and feasibility of transarterial embolization, a minimally invasive procedure, for children with certain types of soft tissue sarcomas. This method aims to reduce blood flow to tumors that cannot be surgically removed or have not responded to standard treatments, potentially helping to manage the condition. Eligible participants are children aged 2-18 years with a specific type of tumor that prior imaging has shown to have significant blood supply.
As an unphased trial, this study provides a unique opportunity for participants to contribute to pioneering research that could lead to new treatment options.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that transarterial embolization is safe for pediatric soft tissue sarcoma?
Research shows that transarterial embolization is usually well-tolerated in children with certain health issues. Studies have demonstrated that this treatment effectively stops bleeding during emergencies, with few serious side effects. Although this trial focuses on pediatric soft tissue sarcomas, similar procedures have proven safe in other cases. As this trial is in the early stages, the main goal is to ensure the treatment's safety for participants. Any unexpected side effects will be closely monitored.12345
Why are researchers excited about this trial?
Transarterial Embolization is unique because it offers a targeted approach to treating soft tissue sarcoma. Unlike traditional treatments like surgery, chemotherapy, or radiation, which can affect a large area of the body, this therapy delivers treatment directly to the tumor's blood supply. By blocking the blood vessels that feed the tumor, it aims to cut off the nutrients the tumor needs to grow. Researchers are excited about this technique because it has the potential to be less invasive and reduce the side effects compared to more systemic treatments.
What evidence suggests that transarterial embolization might be an effective treatment for soft tissue sarcoma?
Research has shown that transarterial embolization can effectively treat soft tissue sarcomas, which are cancers that start in the tissues connecting or supporting other body parts. This treatment cuts off the tumor's blood supply, helping to shrink it and slow its growth. In this trial, participants will receive transarterial embolization to assess its effectiveness in reducing symptoms and controlling tumors locally. Although often used with chemotherapy, researchers are exploring bland embolization (without drugs) for similar benefits. Previous studies have shown promising results in managing symptoms and controlling tumor growth in patients with similar conditions.678910
Who Is on the Research Team?
Junaid Raja, MD, MSPH, FACP
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for pediatric patients aged 2-18 with incurable hypervascular soft tissue sarcomas. They must weigh at least 20 kg and have a tumor that's at least 3 cm with significant blood supply, not planned for surgery or radiation during the study, and no severe allergies to iodinated contrast.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo angiography and transarterial embolization of tumors
Post-procedural Follow-up
Participants return for a clinic visit to assess adverse effects and complete follow-up surveys
Extended Follow-up
Participants complete PedsQL and VAS surveys and undergo imaging to assess tumoral response
What Are the Treatments Tested in This Trial?
Interventions
- Transarterial Embolization
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor